Digital Healthcare Partners (DHP), a digital healthcare startup investment firm, has released its investment performance for 2024. DHP reviewed a total of 326 digital healthcare startups in 2024, marking the firm's largest deal sourcing performance since its founding. This represents a more than threefold increase in just four years compared to the approximately 100 startups reviewed in 2020. Through this, DHP has actively pursued investment review activities, launching new programs such as the "DHP Physician Entrepreneur Bootcamp."
DHP has made new investments in eight startups it reviewed, representing approximately 2.4% of the total companies reviewed. The new investment portfolio includes FixUpHealth (a musculoskeletal remote rehabilitation monitoring platform), MyHub (a medical AI service platform), Compass Diagnostics (a compact medical device for infertility hormone testing), MindHub (a cognitive impairment rehabilitation platform for brain disease patients), WDT (a Japanese senior care AI platform), Gravity Labs (reward-based healthcare), AinB (generative AI-based antibody drug development), and PurpleAI (a neurological disease diagnosis AI). Through these investments, DHP has accumulated a total of 47 digital healthcare startups since its founding in 2016.
Key trends in new startup investments in 2024 include a focus on artificial intelligence (AI), senior care, and global market expansion. Seven of the eight newly invested companies are healthcare startups leveraging AI, highlighting senior care startups addressing Korea's rapidly aging population. Active investments were also made in companies targeting the global market, such as FixUp Health and Compass Diagnostics.
DHP was selected as a TIPS operator by the Ministry of SMEs and Startups in July 2024. Through this program, DHP successfully recommended MindHub and WDT, achieving a 100% TIPS recommendation success rate. In 2025, DHP plans to actively recommend both general TIPS and deep-tech TIPS.
DHP announced that every startup it received investment proposals for through 2024 accepted its investment proposal, a recognition of DHP's expertise and differentiation as a specialized digital healthcare investment firm. Orange Biomed CEO Park Ye-seul stated, "Receiving DHP's investment validated our company and allowed us to actively leverage IR opportunities and our network within the medical community."
DHP plans to continue its active investment in the digital healthcare sector in 2025. CEO Choi Yoon-seop stated, "We've seen a significant increase in the number of healthcare startups seeking DHP investment in 2024, demonstrating their elevated market presence. We plan to invest even more aggressively in 2025." DHP specifically announced plans to focus its investments on "10X Healthcare" startups, focusing on keywords such as artificial intelligence, seniors, and the global market.
- See more related articles
You must be logged in to post a comment.